Table of Contents Author Guidelines Submit a Manuscript
Journal of Cancer Epidemiology
Volume 2012, Article ID 819210, 9 pages
http://dx.doi.org/10.1155/2012/819210
Research Article

Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer

1Outcomes Insights, Inc., Outcomes Research, Westlake Village, CA 91632, USA
2Genentech, Inc., Clinical Development, South San Francisco, CA 94080, USA
3Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, MD 21205, USA

Received 3 November 2011; Accepted 27 January 2012

Academic Editor: Jon Fryzek

Copyright © 2012 Mark D. Danese et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. S. Barnholtz-Sloan, A. E. Sloan, F. G. Davis, F. D. Vigneau, P. Lai, and R. E. Sawaya, “Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2865–2872, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. K. D. Miller, T. Weathers, L. G. Haney et al., “Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival,” Annals of Oncology, vol. 14, no. 7, pp. 1072–1077, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Leyland-Jones, “Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases,” Journal of Clinical Oncology, vol. 27, no. 31, pp. 5278–5286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. N. U. Lin and E. P. Winer, “Brain metastases: the HER2 paradigm,” Clinical Cancer Research, vol. 13, no. 6, pp. 1648–1655, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Tsukada, A. Fouad, J. W. Pickren, and W. W. Lane, “Central nervous system metastasis from breast carcinoma. Autopsy study,” Cancer, vol. 52, no. 12, pp. 2349–2354, 1983. View at Google Scholar · View at Scopus
  6. May 2011, http://www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf.
  7. C. A. Hudis, “Trastuzumab—mechanism of action and use in clinical practice,” New England Journal of Medicine, vol. 357, no. 1, pp. 39–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Baselga, D. Tripathy, J. Mendelsohn et al., “Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 14, no. 3, pp. 737–744, 1996. View at Google Scholar · View at Scopus
  9. M. A. Cobleigh, C. L. Vogel, D. Tripathy et al., “Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease,” Journal of Clinical Oncology, vol. 17, no. 9, pp. 2639–2648, 1999. View at Google Scholar · View at Scopus
  10. C. L. Vogel, M. A. Cobleigh, D. Tripathy et al., “Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 719–726, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Leyland-Jones, K. Gelmon, J. P. Ayoub et al., “Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel,” Journal of Clinical Oncology, vol. 21, no. 21, pp. 3965–3971, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Baselga, X. Carbonell, N. J. Castañeda-Soto et al., “Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule,” Journal of Clinical Oncology, vol. 23, no. 10, pp. 2162–2171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2,” New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Marty, F. Cognetti, D. Maraninchi et al., “Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group,” Journal of Clinical Oncology, vol. 23, no. 19, pp. 4265–4274, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Inoue, K. Nakagami, M. Mizutani et al., “Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group,” Breast Cancer Research and Treatment, vol. 119, no. 1, pp. 127–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Dawood, K. Broglio, F. J. Esteva et al., “Defining prognosis for women with breast cancer and CNS metastases by HER2 status,” Annals of Oncology, vol. 19, no. 7, pp. 1242–1248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Bartsch, A. Rottenfusser, C. Wenzel et al., “Trastuzumab prolongs overall survival in patients with brain metastases from HER2 positive breast cancer,” Journal of Neuro-Oncology, vol. 85, no. 3, pp. 311–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. Warren, C. N. Klabunde, D. Schrag, P. B. Bach, and G. F. Riley, “Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population,” Medical Care, vol. 40, no. 8, pp. 3–18, 2002. View at Google Scholar · View at Scopus
  19. May 2011, http://seer.cancer.gov/about/.
  20. May 2011, http://healthservices.cancer.gov/seermedicare/overview/linked.html.
  21. Practice Management Information Corporation, ICD-9-CM: International Classification of Diseases Ninth Revision, Clinical Modification Sixth Revision, 2006, PCIM, Los Angeles, Calif, USA, 2005.
  22. Practice Management Information Corporation, HCPCS: Health Care Procedure Coding System, National Level II Medicare Codes, 2006, PCIM, Los Angeles, Calif, USA, 2005.
  23. May 2011, http://seer.cancer.gov/manuals/codeman.pdf.
  24. C. N. Klabunde, A. L. Potosky, J. M. Legler, and J. L. Warren, “Development of a comorbidity index using physician claims data,” Journal of Clinical Epidemiology, vol. 53, no. 12, pp. 1258–1267, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. May 2011, http://healthservices.cancer.gov/seermedicare/program/remove.ruleout.dxcodes.macro.txt.
  26. May 2011, http://healthservices.cancer.gov/seermedicare/program/charlson.comorbidity.macro.txt.
  27. R. A. Deyo, D. C. Cherkin, and M. A. Ciol, “Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases,” Journal of Clinical Epidemiology, vol. 45, no. 6, pp. 613–619, 1992. View at Publisher · View at Google Scholar · View at Scopus
  28. M. E. Charlson, P. Pompei, K. A. Ales, and C. R. MacKenzie, “A new method of classifying prognostic comorbidity in longitudinal studies: development and validation,” Journal of Chronic Diseases, vol. 40, no. 5, pp. 373–383, 1987. View at Google Scholar · View at Scopus
  29. P. S. Romano, L. L. Roos, H. S. Luft, J. G. Jollis, and K. Doliszny, “A comparison of administrative versus clinical data: coronary artery bypass surgery as an example,” Journal of Clinical Epidemiology, vol. 47, no. 3, pp. 249–260, 1994. View at Publisher · View at Google Scholar · View at Scopus
  30. M. E. Stokes, D. Thompson, E. L. Montoya, M. C. Weinstein, E. P. Winer, and C. C. Earle, “Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data,” Value in Health, vol. 11, no. 2, pp. 213–220, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. E. B. Lamont, J. E. Herndon, J. C. Weeks et al., “Measuring disease-free survival and cancer relapse using medicare claims from CALGB breast cancer trial participants (companion to 9344),” Journal of the National Cancer Institute, vol. 98, no. 18, pp. 1335–1338, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. A. F. Eichler and E. B. Lamont, “Utility of administrative claims data for the study of brain metastases: a validation study,” Journal of Neuro-Oncology, vol. 95, no. 3, pp. 427–431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Suissa, “Immortal time bias in pharmacoepidemiology,” American Journal of Epidemiology, vol. 167, no. 4, pp. 492–499, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. T. M. Therneau and P. M. Grambsch, Modeling Survival Data: Extending the Cox Model, Springer, New York, NY, USA, 2000.
  35. A. M. Brufsky, M. Mayer, H. S. Rugo et al., “Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER,” Clinical Cancer Research, vol. 17, no. 14, pp. 4834–4843, 2011. View at Publisher · View at Google Scholar
  36. Y. H. Park, M. J. Park, S. H. Ji et al., “Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients,” British Journal of Cancer, vol. 100, no. 6, pp. 894–900, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. H. J. Stemmler, S. Kahlert, W. Siekiera, M. Untch, B. Heinrich, and V. Heinemann, “Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer,” Breast, vol. 15, no. 2, pp. 219–225, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Souglakos, L. Vamvakas, S. Apostolaki et al., “Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status,” Breast Cancer Research, vol. 8, no. 4, article no. R36, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. A. J. Clayton, S. Danson, S. Jolly et al., “Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer,” British Journal of Cancer, vol. 91, no. 4, pp. 639–643, 2004. View at Google Scholar · View at Scopus
  40. J. C. Bendell, S. M. Domchek, H. J. Burstein et al., “Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma,” Cancer, vol. 97, no. 12, pp. 2972–2977, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Yau, C. Swanton, S. Chua et al., “Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab,” Acta Oncologica, vol. 45, no. 2, pp. 196–201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. B. C. Pestalozzi, D. Zahrieh, K. N. Price et al., “Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG),” Annals of Oncology, vol. 17, no. 6, pp. 935–944, 2006. View at Publisher · View at Google Scholar · View at Scopus